Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy

Hongyu WangMelanie KjarsgaardTerence HoJohn D. Brannan and Parameswaran Nair

Abstract

Background

Sputum induction with hypertonic saline in obstructive airway diseases is generally safe. However, saline induces bronchoconstriction in some patients despite pre-medication with Salbutamol. Our objectives were to investigate the predictors of failure of Salbutamol to protect against saline-induced-bronchoconstriction in patients with asthma and COPD and to evaluate implications for asthma therapy.

Methods

Retrospective survey on a database of 3565 patients with obstructive airway diseases who had sputum induced with hypertonic saline. The effect of baseline FEV1, bronchitis and concomitant medication on saline-induced-bronchoconstriction (≥ 15% drop in FEV1) were examined by logistic regression analysis. A subgroup had this re-examined 8–12 weeks after decreasing long-acting-beta-2-agonist dose or after adding Montelukast, which included an assessment of mast cell activity in sputum.

Results

222 (6.2%) patients had saline-induced-bronchoconstriction despite pre-treatment with inhaled Salbutamol. Baseline airflow obstruction (FEV1% predicted < 60% OR 3.29, p < 0.001) and long-acting-beta-agonist use (OR 2.02, p = 0.001), but not bronchitis, were predictors of saline-induced-bronchoconstriction, which decreased when long-acting-beta-agonist dose was decreased. Refractoriness to subsequent bronchodilation was associated with mast cell activity and was attenuated by Montelukast.

Conclusion

Sputum induction with saline provides information on bronchitis and additional physiological data on tolerance to beta-agonists and mast cell activity that may have implications for clinical therapy.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Jason K Lee on Twitter: "Potential treatment for pollen food syndrom… https://t.co/SHnw9UVPnw, see more https://t.co/CpGiFuOOYd
23mreplyretweetfavorite
Interasma Top story: @worldallergy: '#EAACI2018 Understanding phenotypes and endotypes in… https://t.co/WcFkKLobbc, see more https://t.co/CpGiFuOOYd
2hreplyretweetfavorite
Interasma Top story: EAACI on Twitter: "Announcing #EAACI2018 #SisterSocietySymposium SSS… https://t.co/Wic8jRgFE8, see more https://t.co/CpGiFuOOYd
6hreplyretweetfavorite
Interasma Top story: Graham Roberts on Twitter: "Severe asthma plenary #EAACI2018 - no me… https://t.co/ssW67QWKyG, see more https://t.co/CpGiFuOOYd
19hreplyretweetfavorite
Interasma RT @worldallergy: #EAACI2018 Understanding phenotypes and endotypes in severe #asthma https://t.co/MMyACUQd5c
20hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma